Aurora Kinase C Market Share, Definition, Treatment, Symptoms 2016 Aurora Kinase C Market

Aurora Kinase C Market Share, Size, Treatment, Symptoms,
Pipeline Review, H1 2016: Radiant Insights
Summary
Global Markets Direct's, 'Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/ThreonineProtein Kinase Aurora-C or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on Aurora Kinase C
(Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1)
targeted pipeline therapeutics.
The report provides comprehensive information on the Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein
Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1), targeted therapeutics, complete with
analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and
molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases. Additionally, the report provides an
overview of key players involved in Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or
Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) targeted therapeutics development and features
dormant and discontinued projects.
View Full Report with TOC @ http://www.radiantinsights.com/research/aurora-kinase-c-aurora-3
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Aurora Kinase C (Aurora 3 or
Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1)
- The report reviews Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein
Kinase Aurora-C or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research
institutes based on information derived from company and industry-specific sources